Proceedings of the International scientific and practical conference ―Modern Science: Challenges and Perspectives‖ (February 9-11, 2026) / Publisher website: www.naukainfo.com. - London, United Kingdom, 2026. - 121 p.

112 REFERENCES: 1. Urbas, O. V., Vovk, Z. V., Holodnykh, O. A., et al. (2023). A clinical case of manifestation of primary immunodeficiency diagnosed before as Burkitt’s lymphoma. Modern Pediatrics. Ukraine, 4(132), 104–110. https://doi.org/10.15574/SP.2023.132.104 2. Campo, E., Jaffe, E. S., Cook, J. R., Quintanilla-Martinez, L., Swerdlow, S. H., Anderson, K. C., et al. (2022). The International Consensus Classification of mature lymphoid neoplasms: A report from the Clinical Advisory Committee. Blood. https://doi.org/10.1182/blood.2022015851 3. Riaz, I. B., Faridi, W., Patnaik, M. M., & Abraham, R. S. (2019). A systematic review on predisposition to lymphoid (B- and T-cell) neoplasias in patients with primary immunodeficiencies and immune dysregulatory disorders (inborn errors of immunity). Frontiers in Immunology, 10, 777. https://doi.org/10.3389/fimmu.2019.00777. 4. Forbes, L. R., Eckstein, O. S., Gulati, N., & Peckham-Gregory, E. C. (2021). Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders. Journal of Allergy and Clinical Immunology, 149(2). https://doi.org/10.1016/j.jaci.2021.07.015 5. LeBoeuf, N. R., McDermott, S., & Harris, N. L. (2015). Case 5-2015: A 69- year-old woman with recurrent skin lesions after treatment for lymphoma. The New England Journal of Medicine. https://doi.org/10.1056/NEJMcpc1314241 6. Chen, C., Gu, Y. D., & Geskin, L. J. (2019). A review of primary cutaneous CD30+ lymphoproliferative disorders. Hematology/Oncology Clinics of North America, 33(1), 121–134. https://doi.org/10.1016/j.hoc.2018.08.003 7. Cui, D., Zhang, Y., Chen, L., et al. (2024). CD30 plays a role in T-dependent immune response and T cell proliferation. The FASEB Journal. https://doi.org/10.1096/fj.202301747RR